Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary objective of this clinical study is to assess overall safety and tolerability as
measured by discontinuation rate due to adverse events in doses up to 120 mg/day in relation
to global clinical studies in adult subjects who meet Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV™) criteria for Attention-Deficit/Hyperactivity
Disorder (ADHD).